The various biomarkers, the use of which has become routine when clinically diagnosing glioblastoma patients, include O6-methylguanine DNA methyltransferase (MGMT) (21–24), IDH (25–28), EGFR (29–31), TERT (32–34), tumor suppressor protein (TP53) (9, 35), and phosphatase and tensin homolog (PTEN) (36, 37). This evidence concerns the gene IDH1 and glioblastoma.